Observational studyBMC nephrology2016
Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients.
Observational study in BMC nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 62 citations in OpenAlex.
- Dynamic Medication Challenges in Hemodialysis: Rethinking Medication Therapy Management Strategies Through Longitudinal Trends.Kidney medicine · 2026Article
- Therapeutic drug monitoring of antiepileptic drugs in the West Bank, Palestine: a 25-year retrospective cohort study from a multi-branch laboratory network.BMC neurology · 2026Article
- Assessment of potential drug interactions in rheumatology: a comparative study of decision support software.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Impact of pharmacist-led medication review among hemodialysis patients: a systematic review.Journal of pharmaceutical policy and practice · 2025Article
- Clinical Pertinence and Determinants of Potential Drug-Drug Interactions in Chronic Kidney Disease Patients: A Cross-sectional Study.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2024Article
- An Assessment of Different Decision Support Software from the Perspective of Potential Drug-Drug Interactions in Patients with Chronic Kidney Diseases.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Drug utilisation study in hospitalised chronic kidney disease patients, using World Health Organisation prescribing indicators: an observational study.Journal of pharmaceutical policy and practice · 2024Article
- A multicenter descriptive analysis of anemia management in hemodialysis patients and its association with quality of life.BMC nephrology · 2023Article
- Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis.Pharmacoepidemiology and drug safety · 2022Article
- A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs.BMC cancer · 2022Article
- Assessing the binding interaction of polystyrene sulfonate with amitriptyline in healthy volunteers: a cross-over design - The BIND study.European journal of clinical pharmacology · 2022Article
- Exploring co-dispensed drug use in patients on sevelamer or polystyrene sulfonate to identify potential novel binding interactions: a cross sectional in silico study : Potential novel binding interactions with resins.International journal of clinical pharmacy · 2022Article
- Article
- The Prevalence of Potential Drug-Drug Interactions in CKD-A Retrospective Observational Study of Cerrahpasa Nephrology Unit.Medicina (Kaunas, Lithuania) · 2022Observational
- Assessing the efficacy and safety of Juan Bi Tang for dialysis-related myofascial pain in the fistula arm: Study protocol for a randomized cross-over trial.Frontiers in public health · 2022Article
- A retrospective evaluation of drug-drug interactions in patients admitted to Internal Medicine Departments in Palestinian Hospitals.SAGE open medicine · 2022Article
- Prognostic impact of polypharmacy by drug essentiality in patients on hemodialysis.Scientific reports · 2021Article
- Binding interactions with sevelamer and polystyrene sulfonate in vitro.Pharmacology research & perspectives · 2021Article
- Drug-drug interactions in polypharmacy patients: The impact of renal impairment.Current research in pharmacology and drug discovery · 2021Review
- Impact of Adverse Drug Reactions in Patients with End Stage Renal Disease in Greece.International journal of environmental research and public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aims of this study are to find the prevalence of potential drug-drug interactions (DDIs) in patients with Hemodialysis and identify factors associated with these interactions if present.
methodsThe study was an observational- retrospective cohort study that was conducted in ten hemodialysis units in the West bank, Palestine, between June and August 2015. The data collection form was completed by interviewing the patients in addition to reviewing their medical records. Potential DDIs were reviewed. SPSS program was used for data analysis.
resultsThe study included 275 patients, a total of 930 potential interactions were identified in 245 (89.1 %) patients. Patients were prescribed 1-15 drugs with a mean (± SD) of 7.87 ± 2.44, calcium carbonate was the most common drug prescribed. The most common potential interaction in 114 (41.5 %) patients was Calcium Carbonate/Amlodipine followed by Calcium Carbonate/Aspirin in 76 (27.6 %) cases. Most patients (89.9 %) of the patients had one or more comorbid diseases; hypertension, diabetes and gout were the most common. Univariate analysis showed that the number of potential DDIs were related to the number of diseases, the number of prescribed drugs (P value <0.0001) and the age of the patient (P value = 0.015). The results of multiple linear regression showed a significant positive association between number of potential DDIs with the total number of medications (r = 0.242; p < 0.001).
conclusionThe prevalence of potential drug- drug interactions among hemodialysis patients is very common; they are highly expected and depend on the number of drugs taken by the patients. Many of these potential interactions are considered as preventable drug- related problems, so screening for potential interactions and monitoring regularly is highly needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.